excel: 25397

excel with dem: 20383

remove no baseline cre: 18438

remove no baseline cre: 18279

remove no egfr<10: 18278

remove last date on/before ici: 18117

all

Characteristic N = 18,1171
Age 68 (59, 76)
Gender_Legal_Sex
    Female 8,464 (47%)
    Male 9,653 (53%)
male
    0 8,464 (47%)
    1 9,653 (53%)
Race
    Asian 620 (3.4%)
    Black 545 (3.0%)
    Other/Unknown 827 (4.6%)
    White 16,125 (89%)
Ethnic_Group
    Hispanic 17,022 (94%)
    Non_hispanic 1,095 (6.0%)
ckd_incidence
    0 16,943 (96%)
    1 719 (4.1%)
    Unknown 455
ckd_progression
    0 16,162 (92%)
    1 1,500 (8.5%)
    Unknown 455
eskd_composite
    0 17,557 (99%)
    1 105 (0.6%)
    Unknown 455
ckd_composite
    0 15,400 (87%)
    1 2,262 (13%)
    Unknown 455
survival_1year
    0 10,088 (56%)
    1 8,029 (44%)
survival_2year
    0 14,356 (79%)
    1 3,761 (21%)
survival_3year
    0 15,745 (87%)
    1 2,372 (13%)
survival_4year
    0 16,790 (93%)
    1 1,327 (7.3%)
survival_5year
    0 17,272 (95%)
    1 845 (4.7%)
survival_6year
    0 17,488 (97%)
    1 629 (3.5%)
survival_7year
    0 17,661 (97%)
    1 456 (2.5%)
survival_8year
    0 17,822 (98%)
    1 295 (1.6%)
survival_9year
    0 17,927 (99%)
    1 190 (1.0%)
survival_10year
    0 17,978 (99%)
    1 139 (0.8%)
death_1year
    0 10,088 (56%)
    1 8,029 (44%)
death_2year
    0 6,327 (35%)
    1 11,790 (65%)
death_3year
    0 3,955 (22%)
    1 14,162 (78%)
death_4year
    0 2,628 (15%)
    1 15,489 (85%)
death_5year
    0 1,783 (9.8%)
    1 16,334 (90%)
death_6year
    0 1,154 (6.4%)
    1 16,963 (94%)
death_7year
    0 698 (3.9%)
    1 17,419 (96%)
death_8year
    0 403 (2.2%)
    1 17,714 (98%)
death_9year
    0 213 (1.2%)
    1 17,904 (99%)
death_10year
    0 74 (0.4%)
    1 18,043 (100%)
dm
    0 15,404 (85%)
    1 2,713 (15%)
htn
    0 7,171 (40%)
    1 10,946 (60%)
cad
    0 13,871 (77%)
    1 4,246 (23%)
esrd_kt
    0 18,117 (100%)
ace_arb
    0 10,528 (58%)
    1 7,589 (42%)
diu
    0 8,515 (47%)
    1 9,602 (53%)
ppi
    0 5,199 (29%)
    1 12,918 (71%)
steroids
    0 4,637 (26%)
    1 13,480 (74%)
smoking
    0 8,989 (50%)
    1 9,128 (50%)
Cisplatin
    0 15,764 (87%)
    1 2,353 (13%)
Carboplatin
    0 12,504 (69%)
    1 5,613 (31%)
Pemetrexed
    0 15,752 (87%)
    1 2,365 (13%)
Gemcitabine
    0 16,038 (89%)
    1 2,079 (11%)
Cetuximab
    0 17,685 (98%)
    1 432 (2.4%)
Trastuzumab
    0 17,652 (97%)
    1 465 (2.6%)
VEGF_TKI
    0 16,858 (93%)
    1 1,259 (6.9%)
ckd_stage
    1 8,659 (48%)
    2 6,717 (37%)
    3 2,555 (14%)
    4 175 (1.0%)
    5 11 (<0.1%)
pre_CRE_180days 0.85 (0.70, 1.04)
pre_HGB_180days 12.20 (10.80, 13.50)
    Unknown 19
pre_ALB_180days 4.00 (3.70, 4.30)
    Unknown 105
eGFR_cre 89 (70, 100)
1 Median (Q1, Q3); n (%)

1year

Characteristic N = 8,0291
Age 68 (59, 75)
Gender_Legal_Sex
    Female 3,636 (45%)
    Male 4,393 (55%)
male
    0 3,636 (45%)
    1 4,393 (55%)
Race
    Asian 323 (4.0%)
    Black 261 (3.3%)
    Other/Unknown 402 (5.0%)
    White 7,043 (88%)
Ethnic_Group
    Hispanic 7,547 (94%)
    Non_hispanic 482 (6.0%)
ckd_incidence_1year
    0 8,009 (100%)
    1 20 (0.2%)
ckd_progression_1year
    0 7,723 (96%)
    1 306 (3.8%)
eskd_composite_1year
    0 8,004 (100%)
    1 25 (0.3%)
ckd_composite_1year
    0 7,687 (96%)
    1 342 (4.3%)
dm
    0 6,691 (83%)
    1 1,338 (17%)
htn
    0 3,024 (38%)
    1 5,005 (62%)
cad
    0 5,884 (73%)
    1 2,145 (27%)
ace_arb
    0 4,909 (61%)
    1 3,120 (39%)
diu
    0 3,741 (47%)
    1 4,288 (53%)
ppi
    0 2,363 (29%)
    1 5,666 (71%)
steroids
    0 1,914 (24%)
    1 6,115 (76%)
smoking
    0 4,030 (50%)
    1 3,999 (50%)
Bevacizumab
    0 7,399 (92%)
    1 630 (7.8%)
Cisplatin
    0 6,999 (87%)
    1 1,030 (13%)
Carboplatin
    0 5,524 (69%)
    1 2,505 (31%)
Pemetrexed
    0 6,997 (87%)
    1 1,032 (13%)
Gemcitabine
    0 7,166 (89%)
    1 863 (11%)
Cetuximab
    0 7,829 (98%)
    1 200 (2.5%)
Trastuzumab
    0 7,857 (98%)
    1 172 (2.1%)
VEGF_TKI
    0 7,609 (95%)
    1 420 (5.2%)
ckd_stage
    1 3,988 (50%)
    2 2,726 (34%)
    3 1,207 (15%)
    4 101 (1.3%)
    5 7 (<0.1%)
pre_CRE_180days 0.83 (0.68, 1.03)
pre_HGB_180days 11.60 (10.20, 13.00)
    Unknown 8
pre_ALB_180days 3.80 (3.40, 4.10)
    Unknown 46
eGFR_cre 90 (70, 101)
1 Median (Q1, Q3); n (%)

2year

Characteristic N = 3,7611
Age 68 (58, 76)
Gender_Legal_Sex
    Female 1,856 (49%)
    Male 1,905 (51%)
male
    0 1,856 (49%)
    1 1,905 (51%)
Race
    Asian 129 (3.4%)
    Black 126 (3.4%)
    Other/Unknown 174 (4.6%)
    White 3,332 (89%)
Ethnic_Group
    Hispanic 3,540 (94%)
    Non_hispanic 221 (5.9%)
ckd_incidence_2year
    0 3,634 (97%)
    1 127 (3.4%)
ckd_progression_2year
    0 3,336 (89%)
    1 425 (11%)
eskd_composite_2year
    0 3,739 (99%)
    1 22 (0.6%)
ckd_composite_2year
    0 3,201 (85%)
    1 560 (15%)
dm
    0 3,208 (85%)
    1 553 (15%)
htn
    0 1,517 (40%)
    1 2,244 (60%)
cad
    0 2,941 (78%)
    1 820 (22%)
ace_arb
    0 2,179 (58%)
    1 1,582 (42%)
diu
    0 1,729 (46%)
    1 2,032 (54%)
ppi
    0 1,065 (28%)
    1 2,696 (72%)
steroids
    0 976 (26%)
    1 2,785 (74%)
smoking
    0 1,867 (50%)
    1 1,894 (50%)
Bevacizumab
    0 3,453 (92%)
    1 308 (8.2%)
Cisplatin
    0 3,231 (86%)
    1 530 (14%)
Carboplatin
    0 2,415 (64%)
    1 1,346 (36%)
Pemetrexed
    0 3,226 (86%)
    1 535 (14%)
Gemcitabine
    0 3,244 (86%)
    1 517 (14%)
Cetuximab
    0 3,651 (97%)
    1 110 (2.9%)
Trastuzumab
    0 3,646 (97%)
    1 115 (3.1%)
VEGF_TKI
    0 3,482 (93%)
    1 279 (7.4%)
ckd_stage
    1 1,805 (48%)
    2 1,401 (37%)
    3 517 (14%)
    4 37 (1.0%)
    5 1 (<0.1%)
pre_CRE_180days 0.84 (0.70, 1.03)
pre_HGB_180days 12.40 (11.10, 13.60)
    Unknown 5
pre_ALB_180days 4.10 (3.80, 4.30)
    Unknown 23
eGFR_cre 89 (71, 100)
1 Median (Q1, Q3); n (%)

3year

Characteristic N = 2,3721
Age 68 (60, 76)
Gender_Legal_Sex
    Female 1,152 (49%)
    Male 1,220 (51%)
male
    0 1,152 (49%)
    1 1,220 (51%)
Race
    Asian 81 (3.4%)
    Black 71 (3.0%)
    Other/Unknown 101 (4.3%)
    White 2,119 (89%)
Ethnic_Group
    Hispanic 2,226 (94%)
    Non_hispanic 146 (6.2%)
ckd_incidence_3year
    0 2,218 (94%)
    1 154 (6.5%)
ckd_progression_3year
    0 2,060 (87%)
    1 312 (13%)
eskd_composite_3year
    0 2,353 (99%)
    1 19 (0.8%)
ckd_composite_3year
    0 1,901 (80%)
    1 471 (20%)
dm
    0 2,028 (85%)
    1 344 (15%)
htn
    0 1,003 (42%)
    1 1,369 (58%)
cad
    0 1,857 (78%)
    1 515 (22%)
ace_arb
    0 1,328 (56%)
    1 1,044 (44%)
diu
    0 1,167 (49%)
    1 1,205 (51%)
ppi
    0 689 (29%)
    1 1,683 (71%)
steroids
    0 657 (28%)
    1 1,715 (72%)
smoking
    0 1,184 (50%)
    1 1,188 (50%)
Bevacizumab
    0 2,212 (93%)
    1 160 (6.7%)
Cisplatin
    0 2,035 (86%)
    1 337 (14%)
Carboplatin
    0 1,598 (67%)
    1 774 (33%)
Pemetrexed
    0 2,065 (87%)
    1 307 (13%)
Gemcitabine
    0 2,048 (86%)
    1 324 (14%)
Cetuximab
    0 2,315 (98%)
    1 57 (2.4%)
Trastuzumab
    0 2,283 (96%)
    1 89 (3.8%)
VEGF_TKI
    0 2,149 (91%)
    1 223 (9.4%)
ckd_stage
    1 1,064 (45%)
    2 954 (40%)
    3 333 (14%)
    4 20 (0.8%)
    5 1 (<0.1%)
pre_CRE_180days 0.85 (0.71, 1.04)
pre_HGB_180days 12.60 (11.40, 13.80)
    Unknown 1
pre_ALB_180days 4.20 (3.90, 4.40)
    Unknown 18
eGFR_cre 87 (71, 99)
1 Median (Q1, Q3); n (%)

4year

Characteristic N = 1,3271
Age 69 (60, 76)
Gender_Legal_Sex
    Female 615 (46%)
    Male 712 (54%)
male
    0 615 (46%)
    1 712 (54%)
Race
    Asian 34 (2.6%)
    Black 41 (3.1%)
    Other/Unknown 55 (4.1%)
    White 1,197 (90%)
Ethnic_Group
    Hispanic 1,255 (95%)
    Non_hispanic 72 (5.4%)
ckd_incidence_4year
    0 1,218 (92%)
    1 109 (8.2%)
ckd_progression_4year
    0 1,165 (88%)
    1 162 (12%)
eskd_composite_4year
    0 1,317 (99%)
    1 10 (0.8%)
ckd_composite_4year
    0 1,052 (79%)
    1 275 (21%)
dm
    0 1,153 (87%)
    1 174 (13%)
htn
    0 555 (42%)
    1 772 (58%)
cad
    0 1,073 (81%)
    1 254 (19%)
ace_arb
    0 727 (55%)
    1 600 (45%)
diu
    0 622 (47%)
    1 705 (53%)
ppi
    0 410 (31%)
    1 917 (69%)
steroids
    0 345 (26%)
    1 982 (74%)
smoking
    0 643 (48%)
    1 684 (52%)
Bevacizumab
    0 1,250 (94%)
    1 77 (5.8%)
Cisplatin
    0 1,157 (87%)
    1 170 (13%)
Carboplatin
    0 925 (70%)
    1 402 (30%)
Pemetrexed
    0 1,132 (85%)
    1 195 (15%)
Gemcitabine
    0 1,178 (89%)
    1 149 (11%)
Cetuximab
    0 1,298 (98%)
    1 29 (2.2%)
Trastuzumab
    0 1,295 (98%)
    1 32 (2.4%)
VEGF_TKI
    0 1,195 (90%)
    1 132 (9.9%)
ckd_stage
    1 559 (42%)
    2 579 (44%)
    3 181 (14%)
    4 7 (0.5%)
    5 1 (<0.1%)
pre_CRE_180days 0.88 (0.73, 1.05)
pre_HGB_180days 12.80 (11.50, 13.90)
    Unknown 4
pre_ALB_180days 4.20 (3.90, 4.40)
    Unknown 8
eGFR_cre 86 (70, 98)
1 Median (Q1, Q3); n (%)

5year

Characteristic N = 8451
Age 70 (62, 77)
Gender_Legal_Sex
    Female 386 (46%)
    Male 459 (54%)
male
    0 386 (46%)
    1 459 (54%)
Race
    Asian 15 (1.8%)
    Black 20 (2.4%)
    Other/Unknown 35 (4.1%)
    White 775 (92%)
Ethnic_Group
    Hispanic 794 (94%)
    Non_hispanic 51 (6.0%)
ckd_incidence_5year
    0 762 (90%)
    1 83 (9.8%)
ckd_progression_5year
    0 735 (87%)
    1 110 (13%)
eskd_composite_5year
    0 838 (99%)
    1 7 (0.8%)
ckd_composite_5year
    0 651 (77%)
    1 194 (23%)
dm
    0 728 (86%)
    1 117 (14%)
htn
    0 346 (41%)
    1 499 (59%)
cad
    0 661 (78%)
    1 184 (22%)
ace_arb
    0 435 (51%)
    1 410 (49%)
diu
    0 411 (49%)
    1 434 (51%)
ppi
    0 229 (27%)
    1 616 (73%)
steroids
    0 231 (27%)
    1 614 (73%)
smoking
    0 402 (48%)
    1 443 (52%)
Bevacizumab
    0 798 (94%)
    1 47 (5.6%)
Cisplatin
    0 750 (89%)
    1 95 (11%)
Carboplatin
    0 633 (75%)
    1 212 (25%)
Pemetrexed
    0 725 (86%)
    1 120 (14%)
Gemcitabine
    0 766 (91%)
    1 79 (9.3%)
Cetuximab
    0 832 (98%)
    1 13 (1.5%)
Trastuzumab
    0 825 (98%)
    1 20 (2.4%)
VEGF_TKI
    0 756 (89%)
    1 89 (11%)
ckd_stage
    1 365 (43%)
    2 359 (42%)
    3 117 (14%)
    4 3 (0.4%)
    5 1 (0.1%)
pre_CRE_180days 0.88 (0.73, 1.06)
pre_HGB_180days 12.90 (11.50, 14.00)
pre_ALB_180days 4.20 (3.90, 4.40)
    Unknown 3
eGFR_cre 87 (69, 98)
1 Median (Q1, Q3); n (%)

6year

Characteristic N = 6291
Age 70 (61, 78)
Gender_Legal_Sex
    Female 285 (45%)
    Male 344 (55%)
male
    0 285 (45%)
    1 344 (55%)
Race
    Asian 19 (3.0%)
    Black 3 (0.5%)
    Other/Unknown 19 (3.0%)
    White 588 (93%)
Ethnic_Group
    Hispanic 596 (95%)
    Non_hispanic 33 (5.2%)
ckd_incidence_6year
    0 548 (87%)
    1 81 (13%)
ckd_progression_6year
    0 564 (90%)
    1 65 (10%)
eskd_composite_6year
    0 623 (99%)
    1 6 (1.0%)
ckd_composite_6year
    0 480 (76%)
    1 149 (24%)
dm
    0 561 (89%)
    1 68 (11%)
htn
    0 263 (42%)
    1 366 (58%)
cad
    0 501 (80%)
    1 128 (20%)
ace_arb
    0 332 (53%)
    1 297 (47%)
diu
    0 282 (45%)
    1 347 (55%)
ppi
    0 184 (29%)
    1 445 (71%)
steroids
    0 184 (29%)
    1 445 (71%)
smoking
    0 294 (47%)
    1 335 (53%)
Bevacizumab
    0 600 (95%)
    1 29 (4.6%)
Cisplatin
    0 562 (89%)
    1 67 (11%)
Carboplatin
    0 478 (76%)
    1 151 (24%)
Pemetrexed
    0 557 (89%)
    1 72 (11%)
Gemcitabine
    0 567 (90%)
    1 62 (9.9%)
Cetuximab
    0 618 (98%)
    1 11 (1.7%)
Trastuzumab
    0 615 (98%)
    1 14 (2.2%)
VEGF_TKI
    0 584 (93%)
    1 45 (7.2%)
ckd_stage
    1 298 (47%)
    2 254 (40%)
    3 74 (12%)
    4 3 (0.5%)
    5 0 (0%)
pre_CRE_180days 0.86 (0.72, 1.02)
pre_HGB_180days 12.95 (11.65, 14.20)
    Unknown 1
pre_ALB_180days 4.20 (3.90, 4.40)
    Unknown 4
eGFR_cre 89 (73, 99)
1 Median (Q1, Q3); n (%)

7year

Characteristic N = 4561
Age 70 (61, 76)
Gender_Legal_Sex
    Female 220 (48%)
    Male 236 (52%)
male
    0 220 (48%)
    1 236 (52%)
Race
    Asian 10 (2.2%)
    Black 8 (1.8%)
    Other/Unknown 15 (3.3%)
    White 423 (93%)
Ethnic_Group
    Hispanic 422 (93%)
    Non_hispanic 34 (7.5%)
ckd_incidence_7year
    0 410 (90%)
    1 46 (10%)
ckd_progression_7year
    0 406 (89%)
    1 50 (11%)
eskd_composite_7year
    0 451 (99%)
    1 5 (1.1%)
ckd_composite_7year
    0 356 (78%)
    1 100 (22%)
dm
    0 417 (91%)
    1 39 (8.6%)
htn
    0 195 (43%)
    1 261 (57%)
cad
    0 365 (80%)
    1 91 (20%)
ace_arb
    0 246 (54%)
    1 210 (46%)
diu
    0 229 (50%)
    1 227 (50%)
ppi
    0 113 (25%)
    1 343 (75%)
steroids
    0 119 (26%)
    1 337 (74%)
smoking
    0 225 (49%)
    1 231 (51%)
Bevacizumab
    0 434 (95%)
    1 22 (4.8%)
Cisplatin
    0 383 (84%)
    1 73 (16%)
Carboplatin
    0 345 (76%)
    1 111 (24%)
Pemetrexed
    0 408 (89%)
    1 48 (11%)
Gemcitabine
    0 410 (90%)
    1 46 (10%)
Cetuximab
    0 449 (98%)
    1 7 (1.5%)
Trastuzumab
    0 446 (98%)
    1 10 (2.2%)
VEGF_TKI
    0 426 (93%)
    1 30 (6.6%)
ckd_stage
    1 214 (47%)
    2 186 (41%)
    3 55 (12%)
    4 1 (0.2%)
    5 0 (0%)
pre_CRE_180days 0.87 (0.72, 1.03)
pre_HGB_180days 13.30 (12.10, 14.30)
pre_ALB_180days 4.20 (3.90, 4.40)
eGFR_cre 88 (73, 99)
1 Median (Q1, Q3); n (%)

8year

Characteristic N = 2951
Age 68 (60, 77)
Gender_Legal_Sex
    Female 146 (49%)
    Male 149 (51%)
male
    0 146 (49%)
    1 149 (51%)
Race
    Asian 4 (1.4%)
    Black 8 (2.7%)
    Other/Unknown 16 (5.4%)
    White 267 (91%)
Ethnic_Group
    Hispanic 279 (95%)
    Non_hispanic 16 (5.4%)
ckd_incidence_8year
    0 262 (89%)
    1 33 (11%)
ckd_progression_8year
    0 261 (88%)
    1 34 (12%)
eskd_composite_8year
    0 289 (98%)
    1 6 (2.0%)
ckd_composite_8year
    0 227 (77%)
    1 68 (23%)
dm
    0 256 (87%)
    1 39 (13%)
htn
    0 113 (38%)
    1 182 (62%)
cad
    0 247 (84%)
    1 48 (16%)
ace_arb
    0 159 (54%)
    1 136 (46%)
diu
    0 135 (46%)
    1 160 (54%)
ppi
    0 60 (20%)
    1 235 (80%)
steroids
    0 67 (23%)
    1 228 (77%)
smoking
    0 132 (45%)
    1 163 (55%)
Bevacizumab
    0 283 (96%)
    1 12 (4.1%)
Cisplatin
    0 268 (91%)
    1 27 (9.2%)
Carboplatin
    0 235 (80%)
    1 60 (20%)
Pemetrexed
    0 266 (90%)
    1 29 (9.8%)
Gemcitabine
    0 272 (92%)
    1 23 (7.8%)
Cetuximab
    0 293 (99%)
    1 2 (0.7%)
Trastuzumab
    0 287 (97%)
    1 8 (2.7%)
VEGF_TKI
    0 274 (93%)
    1 21 (7.1%)
ckd_stage
    1 150 (51%)
    2 109 (37%)
    3 34 (12%)
    4 2 (0.7%)
    5 0 (0%)
pre_CRE_180days 0.86 (0.71, 1.06)
pre_HGB_180days 13.20 (12.10, 14.00)
pre_ALB_180days 4.10 (3.90, 4.40)
    Unknown 1
eGFR_cre 91 (70, 102)
1 Median (Q1, Q3); n (%)

9year

Characteristic N = 1901
Age 71 (61, 78)
Gender_Legal_Sex
    Female 76 (40%)
    Male 114 (60%)
male
    0 76 (40%)
    1 114 (60%)
Race
    Asian 3 (1.6%)
    Black 5 (2.6%)
    Other/Unknown 6 (3.2%)
    White 176 (93%)
Ethnic_Group
    Hispanic 168 (88%)
    Non_hispanic 22 (12%)
ckd_incidence_9year
    0 154 (81%)
    1 36 (19%)
ckd_progression_9year
    0 173 (91%)
    1 17 (8.9%)
eskd_composite_9year
    0 187 (98%)
    1 3 (1.6%)
ckd_composite_9year
    0 136 (72%)
    1 54 (28%)
dm
    0 168 (88%)
    1 22 (12%)
htn
    0 79 (42%)
    1 111 (58%)
cad
    0 151 (79%)
    1 39 (21%)
ace_arb
    0 91 (48%)
    1 99 (52%)
diu
    0 94 (49%)
    1 96 (51%)
ppi
    0 41 (22%)
    1 149 (78%)
steroids
    0 52 (27%)
    1 138 (73%)
smoking
    0 96 (51%)
    1 94 (49%)
Bevacizumab
    0 184 (97%)
    1 6 (3.2%)
Cisplatin
    0 175 (92%)
    1 15 (7.9%)
Carboplatin
    0 162 (85%)
    1 28 (15%)
Pemetrexed
    0 175 (92%)
    1 15 (7.9%)
Gemcitabine
    0 181 (95%)
    1 9 (4.7%)
Cetuximab
    0 189 (99%)
    1 1 (0.5%)
Trastuzumab
    0 188 (99%)
    1 2 (1.1%)
VEGF_TKI
    0 179 (94%)
    1 11 (5.8%)
ckd_stage
    1 106 (56%)
    2 66 (35%)
    3 17 (8.9%)
    4 1 (0.5%)
    5 0 (0%)
pre_CRE_180days 0.86 (0.74, 1.03)
pre_HGB_180days 12.90 (12.00, 14.10)
pre_ALB_180days 4.10 (3.85, 4.40)
    Unknown 2
eGFR_cre 91 (76, 101)
1 Median (Q1, Q3); n (%)

10year

Characteristic N = 1901
Age 71 (61, 78)
Gender_Legal_Sex
    Female 76 (40%)
    Male 114 (60%)
male
    0 76 (40%)
    1 114 (60%)
Race
    Asian 3 (1.6%)
    Black 5 (2.6%)
    Other/Unknown 6 (3.2%)
    White 176 (93%)
Ethnic_Group
    Hispanic 168 (88%)
    Non_hispanic 22 (12%)
ckd_incidence_9year
    0 154 (81%)
    1 36 (19%)
ckd_progression_9year
    0 173 (91%)
    1 17 (8.9%)
eskd_composite_9year
    0 187 (98%)
    1 3 (1.6%)
ckd_composite_9year
    0 136 (72%)
    1 54 (28%)
dm
    0 168 (88%)
    1 22 (12%)
htn
    0 79 (42%)
    1 111 (58%)
cad
    0 151 (79%)
    1 39 (21%)
ace_arb
    0 91 (48%)
    1 99 (52%)
diu
    0 94 (49%)
    1 96 (51%)
ppi
    0 41 (22%)
    1 149 (78%)
steroids
    0 52 (27%)
    1 138 (73%)
smoking
    0 96 (51%)
    1 94 (49%)
Bevacizumab
    0 184 (97%)
    1 6 (3.2%)
Cisplatin
    0 175 (92%)
    1 15 (7.9%)
Carboplatin
    0 162 (85%)
    1 28 (15%)
Pemetrexed
    0 175 (92%)
    1 15 (7.9%)
Gemcitabine
    0 181 (95%)
    1 9 (4.7%)
Cetuximab
    0 189 (99%)
    1 1 (0.5%)
Trastuzumab
    0 188 (99%)
    1 2 (1.1%)
VEGF_TKI
    0 179 (94%)
    1 11 (5.8%)
ckd_stage
    1 106 (56%)
    2 66 (35%)
    3 17 (8.9%)
    4 1 (0.5%)
    5 0 (0%)
pre_CRE_180days 0.86 (0.74, 1.03)
pre_HGB_180days 12.90 (12.00, 14.10)
pre_ALB_180days 4.10 (3.85, 4.40)
    Unknown 2
eGFR_cre 91 (76, 101)
1 Median (Q1, Q3); n (%) 
final_master_diabetes <- final_master %>% filter(dm==1)

1year

Characteristic N = 1,3381
Age 71 (64, 78)
Gender_Legal_Sex
    Female 483 (36%)
    Male 855 (64%)
male
    0 483 (36%)
    1 855 (64%)
Race
    Asian 55 (4.1%)
    Black 83 (6.2%)
    Other/Unknown 81 (6.1%)
    White 1,119 (84%)
Ethnic_Group
    Hispanic 1,242 (93%)
    Non_hispanic 96 (7.2%)
ckd_incidence_1year
    0 1,334 (100%)
    1 4 (0.3%)
ckd_progression_1year
    0 1,259 (94%)
    1 79 (5.9%)
eskd_composite_1year
    0 1,326 (99%)
    1 12 (0.9%)
ckd_composite_1year
    0 1,248 (93%)
    1 90 (6.7%)
dm
    0 0 (0%)
    1 1,338 (100%)
htn
    0 136 (10%)
    1 1,202 (90%)
cad
    0 698 (52%)
    1 640 (48%)
ace_arb
    0 426 (32%)
    1 912 (68%)
diu
    0 394 (29%)
    1 944 (71%)
ppi
    0 258 (19%)
    1 1,080 (81%)
steroids
    0 190 (14%)
    1 1,148 (86%)
smoking
    0 496 (37%)
    1 842 (63%)
Bevacizumab
    0 1,239 (93%)
    1 99 (7.4%)
Cisplatin
    0 1,157 (86%)
    1 181 (14%)
Carboplatin
    0 886 (66%)
    1 452 (34%)
Pemetrexed
    0 1,172 (88%)
    1 166 (12%)
Gemcitabine
    0 1,172 (88%)
    1 166 (12%)
Cetuximab
    0 1,300 (97%)
    1 38 (2.8%)
Trastuzumab
    0 1,314 (98%)
    1 24 (1.8%)
VEGF_TKI
    0 1,255 (94%)
    1 83 (6.2%)
ckd_stage
    1 496 (37%)
    2 512 (38%)
    3 292 (22%)
    4 34 (2.5%)
    5 4 (0.3%)
pre_CRE_180days 0.93 (0.73, 1.17)
pre_HGB_180days 11.30 (9.90, 12.60)
    Unknown 4
pre_ALB_180days 3.70 (3.30, 4.00)
    Unknown 12
eGFR_cre 80 (61, 96)
1 Median (Q1, Q3); n (%)

2year

Characteristic N = 5531
Age 72 (65, 78)
Gender_Legal_Sex
    Female 207 (37%)
    Male 346 (63%)
male
    0 207 (37%)
    1 346 (63%)
Race
    Asian 25 (4.5%)
    Black 32 (5.8%)
    Other/Unknown 29 (5.2%)
    White 467 (84%)
Ethnic_Group
    Hispanic 519 (94%)
    Non_hispanic 34 (6.1%)
ckd_incidence_2year
    0 530 (96%)
    1 23 (4.2%)
ckd_progression_2year
    0 440 (80%)
    1 113 (20%)
eskd_composite_2year
    0 548 (99%)
    1 5 (0.9%)
ckd_composite_2year
    0 416 (75%)
    1 137 (25%)
dm
    0 0 (0%)
    1 553 (100%)
htn
    0 63 (11%)
    1 490 (89%)
cad
    0 305 (55%)
    1 248 (45%)
ace_arb
    0 138 (25%)
    1 415 (75%)
diu
    0 158 (29%)
    1 395 (71%)
ppi
    0 110 (20%)
    1 443 (80%)
steroids
    0 83 (15%)
    1 470 (85%)
smoking
    0 205 (37%)
    1 348 (63%)
Bevacizumab
    0 514 (93%)
    1 39 (7.1%)
Cisplatin
    0 474 (86%)
    1 79 (14%)
Carboplatin
    0 352 (64%)
    1 201 (36%)
Pemetrexed
    0 475 (86%)
    1 78 (14%)
Gemcitabine
    0 473 (86%)
    1 80 (14%)
Cetuximab
    0 535 (97%)
    1 18 (3.3%)
Trastuzumab
    0 538 (97%)
    1 15 (2.7%)
VEGF_TKI
    0 483 (87%)
    1 70 (13%)
ckd_stage
    1 186 (34%)
    2 230 (42%)
    3 125 (23%)
    4 12 (2.2%)
    5 0 (0%)
pre_CRE_180days 0.94 (0.75, 1.17)
pre_HGB_180days 11.90 (10.60, 13.10)
    Unknown 4
pre_ALB_180days 4.00 (3.70, 4.30)
    Unknown 7
eGFR_cre 79 (60, 95)
1 Median (Q1, Q3); n (%)

3year

Characteristic N = 3441
Age 72 (65, 78)
Gender_Legal_Sex
    Female 131 (38%)
    Male 213 (62%)
male
    0 131 (38%)
    1 213 (62%)
Race
    Asian 11 (3.2%)
    Black 25 (7.3%)
    Other/Unknown 21 (6.1%)
    White 287 (83%)
Ethnic_Group
    Hispanic 323 (94%)
    Non_hispanic 21 (6.1%)
ckd_incidence_3year
    0 319 (93%)
    1 25 (7.3%)
ckd_progression_3year
    0 259 (75%)
    1 85 (25%)
eskd_composite_3year
    0 335 (97%)
    1 9 (2.6%)
ckd_composite_3year
    0 234 (68%)
    1 110 (32%)
dm
    0 0 (0%)
    1 344 (100%)
htn
    0 35 (10%)
    1 309 (90%)
cad
    0 201 (58%)
    1 143 (42%)
ace_arb
    0 91 (26%)
    1 253 (74%)
diu
    0 95 (28%)
    1 249 (72%)
ppi
    0 64 (19%)
    1 280 (81%)
steroids
    0 56 (16%)
    1 288 (84%)
smoking
    0 132 (38%)
    1 212 (62%)
Bevacizumab
    0 317 (92%)
    1 27 (7.8%)
Cisplatin
    0 297 (86%)
    1 47 (14%)
Carboplatin
    0 221 (64%)
    1 123 (36%)
Pemetrexed
    0 304 (88%)
    1 40 (12%)
Gemcitabine
    0 300 (87%)
    1 44 (13%)
Cetuximab
    0 337 (98%)
    1 7 (2.0%)
Trastuzumab
    0 332 (97%)
    1 12 (3.5%)
VEGF_TKI
    0 299 (87%)
    1 45 (13%)
ckd_stage
    1 107 (31%)
    2 146 (42%)
    3 82 (24%)
    4 8 (2.3%)
    5 1 (0.3%)
pre_CRE_180days 0.96 (0.77, 1.18)
pre_HGB_180days 12.20 (10.80, 13.40)
    Unknown 1
pre_ALB_180days 4.00 (3.80, 4.20)
    Unknown 6
eGFR_cre 79 (58, 93)
1 Median (Q1, Q3); n (%)

4year

Characteristic N = 1741
Age 72 (64, 79)
Gender_Legal_Sex
    Female 70 (40%)
    Male 104 (60%)
male
    0 70 (40%)
    1 104 (60%)
Race
    Asian 9 (5.2%)
    Black 14 (8.0%)
    Other/Unknown 7 (4.0%)
    White 144 (83%)
Ethnic_Group
    Hispanic 168 (97%)
    Non_hispanic 6 (3.4%)
ckd_incidence_4year
    0 153 (88%)
    1 21 (12%)
ckd_progression_4year
    0 139 (80%)
    1 35 (20%)
eskd_composite_4year
    0 171 (98%)
    1 3 (1.7%)
ckd_composite_4year
    0 116 (67%)
    1 58 (33%)
dm
    0 0 (0%)
    1 174 (100%)
htn
    0 17 (9.8%)
    1 157 (90%)
cad
    0 110 (63%)
    1 64 (37%)
ace_arb
    0 50 (29%)
    1 124 (71%)
diu
    0 57 (33%)
    1 117 (67%)
ppi
    0 29 (17%)
    1 145 (83%)
steroids
    0 24 (14%)
    1 150 (86%)
smoking
    0 66 (38%)
    1 108 (62%)
Bevacizumab
    0 163 (94%)
    1 11 (6.3%)
Cisplatin
    0 150 (86%)
    1 24 (14%)
Carboplatin
    0 109 (63%)
    1 65 (37%)
Pemetrexed
    0 148 (85%)
    1 26 (15%)
Gemcitabine
    0 150 (86%)
    1 24 (14%)
Cetuximab
    0 166 (95%)
    1 8 (4.6%)
Trastuzumab
    0 171 (98%)
    1 3 (1.7%)
VEGF_TKI
    0 151 (87%)
    1 23 (13%)
ckd_stage
    1 65 (37%)
    2 70 (40%)
    3 37 (21%)
    4 1 (0.6%)
    5 1 (0.6%)
pre_CRE_180days 0.90 (0.75, 1.15)
pre_HGB_180days 12.50 (11.10, 13.40)
    Unknown 2
pre_ALB_180days 4.10 (3.70, 4.30)
    Unknown 3
eGFR_cre 83 (64, 96)
1 Median (Q1, Q3); n (%)

5year

Characteristic N = 1171
Age 74 (68, 79)
Gender_Legal_Sex
    Female 43 (37%)
    Male 74 (63%)
male
    0 43 (37%)
    1 74 (63%)
Race
    Asian 4 (3.4%)
    Black 2 (1.7%)
    Other/Unknown 5 (4.3%)
    White 106 (91%)
Ethnic_Group
    Hispanic 112 (96%)
    Non_hispanic 5 (4.3%)
ckd_incidence_5year
    0 104 (89%)
    1 13 (11%)
ckd_progression_5year
    0 86 (74%)
    1 31 (26%)
eskd_composite_5year
    0 113 (97%)
    1 4 (3.4%)
ckd_composite_5year
    0 73 (62%)
    1 44 (38%)
dm
    0 0 (0%)
    1 117 (100%)
htn
    0 16 (14%)
    1 101 (86%)
cad
    0 64 (55%)
    1 53 (45%)
ace_arb
    0 22 (19%)
    1 95 (81%)
diu
    0 34 (29%)
    1 83 (71%)
ppi
    0 24 (21%)
    1 93 (79%)
steroids
    0 18 (15%)
    1 99 (85%)
smoking
    0 45 (38%)
    1 72 (62%)
Bevacizumab
    0 112 (96%)
    1 5 (4.3%)
Cisplatin
    0 105 (90%)
    1 12 (10%)
Carboplatin
    0 86 (74%)
    1 31 (26%)
Pemetrexed
    0 93 (79%)
    1 24 (21%)
Gemcitabine
    0 106 (91%)
    1 11 (9.4%)
Cetuximab
    0 114 (97%)
    1 3 (2.6%)
Trastuzumab
    0 112 (96%)
    1 5 (4.3%)
VEGF_TKI
    0 97 (83%)
    1 20 (17%)
ckd_stage
    1 40 (34%)
    2 44 (38%)
    3 32 (27%)
    4 1 (0.9%)
    5 0 (0%)
pre_CRE_180days 0.98 (0.79, 1.23)
pre_HGB_180days 12.60 (10.90, 13.90)
pre_ALB_180days 4.10 (3.90, 4.40)
    Unknown 1
eGFR_cre 78 (57, 95)
1 Median (Q1, Q3); n (%)

6year

Characteristic N = 681
Age 76 (67, 82)
Gender_Legal_Sex
    Female 26 (38%)
    Male 42 (62%)
male
    0 26 (38%)
    1 42 (62%)
Race
    Asian 2 (2.9%)
    Black 1 (1.5%)
    Other/Unknown 2 (2.9%)
    White 63 (93%)
Ethnic_Group
    Hispanic 65 (96%)
    Non_hispanic 3 (4.4%)
ckd_incidence_6year
    0 56 (82%)
    1 12 (18%)
ckd_progression_6year
    0 54 (79%)
    1 14 (21%)
eskd_composite_6year
    0 66 (97%)
    1 2 (2.9%)
ckd_composite_6year
    0 42 (62%)
    1 26 (38%)
dm
    0 0 (0%)
    1 68 (100%)
htn
    0 7 (10%)
    1 61 (90%)
cad
    0 38 (56%)
    1 30 (44%)
ace_arb
    0 12 (18%)
    1 56 (82%)
diu
    0 14 (21%)
    1 54 (79%)
ppi
    0 13 (19%)
    1 55 (81%)
steroids
    0 12 (18%)
    1 56 (82%)
smoking
    0 20 (29%)
    1 48 (71%)
Bevacizumab
    0 64 (94%)
    1 4 (5.9%)
Cisplatin
    0 61 (90%)
    1 7 (10%)
Carboplatin
    0 47 (69%)
    1 21 (31%)
Pemetrexed
    0 61 (90%)
    1 7 (10%)
Gemcitabine
    0 58 (85%)
    1 10 (15%)
Cetuximab
    0 67 (99%)
    1 1 (1.5%)
Trastuzumab
    0 67 (99%)
    1 1 (1.5%)
VEGF_TKI
    0 58 (85%)
    1 10 (15%)
ckd_stage
    1 20 (29%)
    2 31 (46%)
    3 16 (24%)
    4 1 (1.5%)
    5 0 (0%)
pre_CRE_180days 0.97 (0.75, 1.20)
pre_HGB_180days 12.40 (11.30, 13.80)
    Unknown 1
pre_ALB_180days 4.20 (3.80, 4.40)
    Unknown 1
eGFR_cre 79 (60, 92)
1 Median (Q1, Q3); n (%)

7year

Characteristic N = 391
Age 74 (67, 82)
Gender_Legal_Sex
    Female 19 (49%)
    Male 20 (51%)
male
    0 19 (49%)
    1 20 (51%)
Race
    Asian 1 (2.6%)
    Black 3 (7.7%)
    Other/Unknown 3 (7.7%)
    White 32 (82%)
Ethnic_Group
    Hispanic 36 (92%)
    Non_hispanic 3 (7.7%)
ckd_incidence_7year
    0 35 (90%)
    1 4 (10%)
ckd_progression_7year
    0 31 (79%)
    1 8 (21%)
eskd_composite_7year
    0 38 (97%)
    1 1 (2.6%)
ckd_composite_7year
    0 26 (67%)
    1 13 (33%)
dm
    0 0 (0%)
    1 39 (100%)
htn
    0 4 (10%)
    1 35 (90%)
cad
    0 22 (56%)
    1 17 (44%)
ace_arb
    0 9 (23%)
    1 30 (77%)
diu
    0 7 (18%)
    1 32 (82%)
ppi
    0 9 (23%)
    1 30 (77%)
steroids
    0 8 (21%)
    1 31 (79%)
smoking
    0 19 (49%)
    1 20 (51%)
Bevacizumab
    0 39 (100%)
Cisplatin
    0 33 (85%)
    1 6 (15%)
Carboplatin
    0 29 (74%)
    1 10 (26%)
Pemetrexed
    0 34 (87%)
    1 5 (13%)
Gemcitabine
    0 36 (92%)
    1 3 (7.7%)
Cetuximab
    0 38 (97%)
    1 1 (2.6%)
Trastuzumab
    0 39 (100%)
VEGF_TKI
    0 36 (92%)
    1 3 (7.7%)
ckd_stage
    1 13 (33%)
    2 17 (44%)
    3 9 (23%)
    4 0 (0%)
    5 0 (0%)
pre_CRE_180days 0.92 (0.72, 1.21)
pre_HGB_180days 12.30 (11.20, 14.00)
pre_ALB_180days 3.90 (3.70, 4.20)
eGFR_cre 81 (62, 94)
1 Median (Q1, Q3); n (%)

8year

Characteristic N = 391
Age 71 (65, 80)
Gender_Legal_Sex
    Female 17 (44%)
    Male 22 (56%)
male
    0 17 (44%)
    1 22 (56%)
Race
    Asian 1 (2.6%)
    Black 3 (7.7%)
    Other/Unknown 5 (13%)
    White 30 (77%)
Ethnic_Group
    Hispanic 36 (92%)
    Non_hispanic 3 (7.7%)
ckd_incidence_8year
    0 35 (90%)
    1 4 (10%)
ckd_progression_8year
    0 32 (82%)
    1 7 (18%)
eskd_composite_8year
    0 38 (97%)
    1 1 (2.6%)
ckd_composite_8year
    0 28 (72%)
    1 11 (28%)
dm
    0 0 (0%)
    1 39 (100%)
htn
    0 8 (21%)
    1 31 (79%)
cad
    0 29 (74%)
    1 10 (26%)
ace_arb
    0 7 (18%)
    1 32 (82%)
diu
    0 13 (33%)
    1 26 (67%)
ppi
    0 6 (15%)
    1 33 (85%)
steroids
    0 6 (15%)
    1 33 (85%)
smoking
    0 16 (41%)
    1 23 (59%)
Bevacizumab
    0 37 (95%)
    1 2 (5.1%)
Cisplatin
    0 35 (90%)
    1 4 (10%)
Carboplatin
    0 26 (67%)
    1 13 (33%)
Pemetrexed
    0 33 (85%)
    1 6 (15%)
Gemcitabine
    0 35 (90%)
    1 4 (10%)
Cetuximab
    0 39 (100%)
Trastuzumab
    0 39 (100%)
VEGF_TKI
    0 34 (87%)
    1 5 (13%)
ckd_stage
    1 17 (44%)
    2 15 (38%)
    3 6 (15%)
    4 1 (2.6%)
    5 0 (0%)
pre_CRE_180days 0.89 (0.71, 1.11)
pre_HGB_180days 12.80 (11.10, 13.90)
pre_ALB_180days 4.10 (3.80, 4.40)
eGFR_cre 77 (67, 101)
1 Median (Q1, Q3); n (%)

9year

Characteristic N = 221
Age 76 (67, 81)
Gender_Legal_Sex
    Female 6 (27%)
    Male 16 (73%)
male
    0 6 (27%)
    1 16 (73%)
Race
    Asian 0 (0%)
    Black 3 (14%)
    Other/Unknown 2 (9.1%)
    White 17 (77%)
Ethnic_Group
    Hispanic 18 (82%)
    Non_hispanic 4 (18%)
ckd_incidence_9year
    0 13 (59%)
    1 9 (41%)
ckd_progression_9year
    0 16 (73%)
    1 6 (27%)
eskd_composite_9year
    0 22 (100%)
    1 0 (0%)
ckd_composite_9year
    0 7 (32%)
    1 15 (68%)
dm
    0 0 (0%)
    1 22 (100%)
htn
    0 2 (9.1%)
    1 20 (91%)
cad
    0 13 (59%)
    1 9 (41%)
ace_arb
    0 3 (14%)
    1 19 (86%)
diu
    0 6 (27%)
    1 16 (73%)
ppi
    0 6 (27%)
    1 16 (73%)
steroids
    0 7 (32%)
    1 15 (68%)
smoking
    0 9 (41%)
    1 13 (59%)
Bevacizumab
    0 21 (95%)
    1 1 (4.5%)
Cisplatin
    0 21 (95%)
    1 1 (4.5%)
Carboplatin
    0 19 (86%)
    1 3 (14%)
Pemetrexed
    0 21 (95%)
    1 1 (4.5%)
Gemcitabine
    0 19 (86%)
    1 3 (14%)
Cetuximab
    0 22 (100%)
Trastuzumab
    0 22 (100%)
VEGF_TKI
    0 21 (95%)
    1 1 (4.5%)
ckd_stage
    1 9 (41%)
    2 7 (32%)
    3 6 (27%)
    4 0 (0%)
    5 0 (0%)
pre_CRE_180days 1.01 (0.78, 1.43)
pre_HGB_180days 12.15 (10.60, 13.40)
pre_ALB_180days 4.00 (3.80, 4.20)
eGFR_cre 81 (59, 92)
1 Median (Q1, Q3); n (%)

10year

Characteristic N = 221
Age 76 (67, 81)
Gender_Legal_Sex
    Female 6 (27%)
    Male 16 (73%)
male
    0 6 (27%)
    1 16 (73%)
Race
    Asian 0 (0%)
    Black 3 (14%)
    Other/Unknown 2 (9.1%)
    White 17 (77%)
Ethnic_Group
    Hispanic 18 (82%)
    Non_hispanic 4 (18%)
ckd_incidence_9year
    0 13 (59%)
    1 9 (41%)
ckd_progression_9year
    0 16 (73%)
    1 6 (27%)
eskd_composite_9year
    0 22 (100%)
    1 0 (0%)
ckd_composite_9year
    0 7 (32%)
    1 15 (68%)
dm
    0 0 (0%)
    1 22 (100%)
htn
    0 2 (9.1%)
    1 20 (91%)
cad
    0 13 (59%)
    1 9 (41%)
ace_arb
    0 3 (14%)
    1 19 (86%)
diu
    0 6 (27%)
    1 16 (73%)
ppi
    0 6 (27%)
    1 16 (73%)
steroids
    0 7 (32%)
    1 15 (68%)
smoking
    0 9 (41%)
    1 13 (59%)
Bevacizumab
    0 21 (95%)
    1 1 (4.5%)
Cisplatin
    0 21 (95%)
    1 1 (4.5%)
Carboplatin
    0 19 (86%)
    1 3 (14%)
Pemetrexed
    0 21 (95%)
    1 1 (4.5%)
Gemcitabine
    0 19 (86%)
    1 3 (14%)
Cetuximab
    0 22 (100%)
Trastuzumab
    0 22 (100%)
VEGF_TKI
    0 21 (95%)
    1 1 (4.5%)
ckd_stage
    1 9 (41%)
    2 7 (32%)
    3 6 (27%)
    4 0 (0%)
    5 0 (0%)
pre_CRE_180days 1.01 (0.78, 1.43)
pre_HGB_180days 12.15 (10.60, 13.40)
pre_ALB_180days 4.00 (3.80, 4.20)
eGFR_cre 81 (59, 92)
1 Median (Q1, Q3); n (%) 
##                  
##                     0   1
##   stage 1         340  25
##   stage 2         300  59
##   stage 3 or more  11 110
Characteristic N OR1 95% CI1 p-value
Age 845 1.07 1.06, 1.09 <0.001
Gender_Legal_Sex 845


    Female
— —
    Male
0.96 0.70, 1.33 0.821
male 845


    0
— —
    1
0.96 0.70, 1.33 0.821
Race 845


    Asian
— —
    Black
0.92 0.20, 4.46 0.911
    Other/Unknown
0.57 0.13, 2.58 0.444
    White
0.83 0.28, 3.01 0.746
Ethnic_Group 845


    Hispanic
— —
    Non_hispanic
0.71 0.32, 1.41 0.354
dm 845


    0
— —
    1
2.32 1.53, 3.51 <0.001
htn 845


    0
— —
    1
3.06 2.12, 4.48 <0.001
cad 845


    0
— —
    1
2.04 1.42, 2.91 <0.001
ace_arb 845


    0
— —
    1
3.03 2.17, 4.29 <0.001
diu 845


    0
— —
    1
2.61 1.87, 3.70 <0.001
ppi 845


    0
— —
    1
1.85 1.25, 2.79 0.003
steroids 845


    0
— —
    1
1.04 0.73, 1.50 0.849
smoking 845


    0
— —
    1
1.43 1.04, 1.99 0.030
ckd_stage_3 845


    stage 1
— —
    stage 2
2.67 1.65, 4.45 <0.001
    stage 3 or more
136 67.5, 300 <0.001
Bevacizumab 845


    0
— —
    1
1.16 0.57, 2.22 0.666
Cisplatin 845


    0
— —
    1
1.08 0.64, 1.76 0.758
Carboplatin 845


    0
— —
    1
1.33 0.93, 1.90 0.117
Pemetrexed 845


    0
— —
    1
2.03 1.33, 3.06 <0.001
Gemcitabine 845


    0
— —
    1
1.75 1.05, 2.85 0.029
Cetuximab 845


    0
— —
    1
0.28 0.02, 1.41 0.217
Trastuzumab 845


    0
— —
    1
1.12 0.36, 2.94 0.826
VEGF_TKI 845


    0
— —
    1
2.30 1.44, 3.64 <0.001
pre_CRE_180days 845 123 56.4, 283 <0.001
1 OR = Odds Ratio, CI = Confidence Interval